# | Title | Journal | Year | Citations |
---|
1 | Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation | Therapeutic Advances in Gastroenterology | 2013 | 716 |
2 | Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ | Therapeutic Advances in Gastroenterology | 2013 | 642 |
3 | Fecal microbiota transplantation: in perspective | Therapeutic Advances in Gastroenterology | 2016 | 302 |
4 | Diagnosis and management of iron deficiency anemia in the 21st century | Therapeutic Advances in Gastroenterology | 2011 | 274 |
5 | Overutilization of proton-pump inhibitors: what the clinician needs to know | Therapeutic Advances in Gastroenterology | 2012 | 255 |
6 | Pancreatic cancer: why is it so hard to treat? | Therapeutic Advances in Gastroenterology | 2013 | 250 |
7 | Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders | Therapeutic Advances in Gastroenterology | 2012 | 248 |
8 | Secondary causes of nonalcoholic fatty liver disease | Therapeutic Advances in Gastroenterology | 2012 | 205 |
9 | Use of probiotics in gastrointestinal disorders: what to recommend? | Therapeutic Advances in Gastroenterology | 2010 | 190 |
10 | The intestinal microbiota dysbiosis andClostridium difficileinfection: is there a relationship with inflammatory bowel disease? | Therapeutic Advances in Gastroenterology | 2013 | 182 |
11 | Fecal microbiota transplantation in relapsing Clostridium difficile infection | Therapeutic Advances in Gastroenterology | 2012 | 173 |
12 | Current status of novel antifibrotic therapies in patients with chronic liver disease | Therapeutic Advances in Gastroenterology | 2011 | 171 |
13 | Immunogenicity of biologics in inflammatory bowel disease | Therapeutic Advances in Gastroenterology | 2018 | 168 |
14 | The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions | Therapeutic Advances in Gastroenterology | 2016 | 152 |
15 | Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection | Therapeutic Advances in Gastroenterology | 2011 | 149 |
16 | The role and utility of faecal markers in inflammatory bowel disease | Therapeutic Advances in Gastroenterology | 2015 | 140 |
17 | Advances in immunotherapy for colorectal cancer: a review | Therapeutic Advances in Gastroenterology | 2020 | 139 |
18 | The emerging role of miRNAs in inflammatory bowel disease: a review | Therapeutic Advances in Gastroenterology | 2015 | 136 |
19 | Treatment of alcoholic liver disease | Therapeutic Advances in Gastroenterology | 2011 | 131 |
20 | Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? | Therapeutic Advances in Gastroenterology | 2012 | 130 |
21 | Nausea: a review of pathophysiology and therapeutics | Therapeutic Advances in Gastroenterology | 2016 | 130 |
22 | The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial | Therapeutic Advances in Gastroenterology | 2009 | 129 |
23 | A randomized trial of a fully covered self-expandable metallic stent versus plastic stents in anastomotic biliary strictures after liver transplantation | Therapeutic Advances in Gastroenterology | 2014 | 128 |
24 | Managing bile acid diarrhoea | Therapeutic Advances in Gastroenterology | 2010 | 127 |
25 | The gut virome: the ‘missing link’ between gut bacteria and host immunity? | Therapeutic Advances in Gastroenterology | 2019 | 127 |
26 | Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial | Therapeutic Advances in Gastroenterology | 2013 | 124 |
27 | Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis | Therapeutic Advances in Gastroenterology | 2016 | 123 |
28 | Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease? | Therapeutic Advances in Gastroenterology | 2013 | 120 |
29 | Review: Treatment options for nonalcoholic fatty liver disease | Therapeutic Advances in Gastroenterology | 2010 | 119 |
30 | Advantages of enteral nutrition over parenteral nutrition | Therapeutic Advances in Gastroenterology | 2013 | 118 |
31 | Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases | Therapeutic Advances in Gastroenterology | 2015 | 115 |
32 | Eosinophilic colitis: epidemiology, clinical features, and current management | Therapeutic Advances in Gastroenterology | 2011 | 114 |
33 | Surveillance for hepatocellular carcinoma: in whom and how? | Therapeutic Advances in Gastroenterology | 2011 | 111 |
34 | The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy | Therapeutic Advances in Gastroenterology | 2012 | 109 |
35 | Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study | Therapeutic Advances in Gastroenterology | 2016 | 105 |
36 | Review: Functional dyspepsia | Therapeutic Advances in Gastroenterology | 2010 | 104 |
37 | Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease | Therapeutic Advances in Gastroenterology | 2011 | 103 |
38 | Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials | Therapeutic Advances in Gastroenterology | 2016 | 100 |
39 | Optimal biliary access point and learning curve for endoscopic ultrasound-guided hepaticogastrostomy with transmural stenting | Therapeutic Advances in Gastroenterology | 2017 | 99 |
40 | Review: Anti-adhesion molecule therapy for inflammatory bowel disease | Therapeutic Advances in Gastroenterology | 2010 | 97 |
41 | Evaluation of regional and whole gut motility using the wireless motility capsule: relevance in clinical practice | Therapeutic Advances in Gastroenterology | 2012 | 97 |
42 | Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date | Therapeutic Advances in Gastroenterology | 2018 | 96 |
43 | The controversial role of Enterococcus faecalis in colorectal cancer | Therapeutic Advances in Gastroenterology | 2018 | 95 |
44 | Pain management in patients with inflammatory bowel disease: insights for the clinician | Therapeutic Advances in Gastroenterology | 2012 | 94 |
45 | Proton-pump inhibitors among adults: a nationwide drug-utilization study | Therapeutic Advances in Gastroenterology | 2018 | 92 |
46 | The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment | Therapeutic Advances in Gastroenterology | 2015 | 90 |
47 | Automated endoscopic detection and classification of colorectal polyps using convolutional neural networks | Therapeutic Advances in Gastroenterology | 2020 | 90 |
48 | Nutritional management of Crohn’s disease | Therapeutic Advances in Gastroenterology | 2013 | 86 |
49 | Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential | Therapeutic Advances in Gastroenterology | 2014 | 85 |
50 | Screening for celiac disease in average-risk and high-risk populations | Therapeutic Advances in Gastroenterology | 2012 | 83 |